Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-29
2006-08-29
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000
Reexamination Certificate
active
07098211
ABSTRACT:
The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
REFERENCES:
patent: 4450165 (1984-05-01), Araki et al.
patent: 4564619 (1986-01-01), Tanaka et al.
patent: 4568677 (1986-02-01), Alker et al.
patent: 4590195 (1986-05-01), Alker et al.
patent: 4723014 (1988-02-01), Anderson et al.
patent: 4820842 (1989-04-01), Anderson et al.
patent: 4876255 (1989-10-01), Franckowiak et al.
patent: 4898865 (1990-02-01), Franckowiak et al.
patent: 5096904 (1992-03-01), Wheeler et al.
patent: 5100892 (1992-03-01), Wheeler et al.
patent: 5258519 (1993-11-01), Wheeler et al.
patent: 5344944 (1994-09-01), Franckowiak et al.
patent: 101 10 747 (2002-09-01), None
patent: 0 116 769 (1984-08-01), None
patent: 0 119 050 (1984-09-01), None
patent: 0 132 375 (1985-01-01), None
patent: 0 185 964 (1986-07-01), None
patent: 0 189 254 (1986-07-01), None
patent: 0 268 273 (1988-05-01), None
patent: 0 287 866 (1988-10-01), None
patent: 0 287 867 (1988-10-01), None
patent: 0 503 079 (1992-09-01), None
patent: 1 302 463 (2003-04-01), None
Forest et al., “A Novel Class of Cardiotonic Agents: Synthesis and Biological Evaluation of 5-Substituted 3,6-Dihydrothiadiazin-2-ones with Cyclic AMP Phosphodiesterase Inhibiting and Myofibrillar Calcium Sensitizing Properties”,Journal of Medicinal Chemistry, American Chemical Society, vol. 35, No. 1, 1992, pp. 163-172, XP002146828, ISSN: 0022-2623.
Rump et al., “Effects of Different Inotropes with Antioxidant Properties on acute Regional Myocardial Ischemia in Isolated Rabbit Hearts”,General Pharamacology, Pergamon Press, Oxford, GB, vol. 26, No. 3, 1995, pp. 603-611, XP000926014, ISSN: 0306-3623.
Baraldi et al., “Synthesis and Calcium Antagonist Activity of Dialkyl 1,4-Dihydro-2,6-Dimethyl-4-(Nitrogenous Heteroaryl)-3,5-Pyridine Dicarboxylates”,Collect. Czech. Chem. Commun., vol. 57, 1992, pp. 169-178, XP009023953.
Alker et al., “Long Action Dihydropyridine Calcium Antagonists”,Journal of Medicinal Chemistry, vol. 33, 1990, pp. 585-591, XP002267026.
Fossheim, “Crystal Structure of the Dihydropyridine Ca2+Antagonist Felodipine. Dihydropyridine Binding Prerequisites Assessed from Crystallographic Data,”J. Med. Chem., vol. 29, pp. 305-307, (1986), American Chemical Society.
Tamazawa et al., “Stereoselectivity of a Potent Calcium Antagonist, 1-Benzyl-3-pyrrolidinyl Methyl 2,6-Dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate,”J. Med. Chem., vol. 29, pp. 2504-2511, (1986) American Chemical Society.
Sunkel et al., “Synthesis of 3-[2,3-Dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl]alkyl 1,4-Dihydropyridine-3,5-dicarboxylate Derivatives as Calcium Channel Modulators,”J. Med. Chem., vol. 35, pp. 2407-2414, (1992), American Chemical Society.
Arrowsmith et al., “Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Derivatives Incorporating Basic Substituents,”J. Med. Chem., vol. 29, pp. 1696-1702, (1986), American Chemical Society, UK.
Alker, et al., “Long-Acting Dihydropyridine Calcium Antagonists. 5. Synthesis and Structure-Activity Relationships for a Series of 2-[[(N-Substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine Calcium Antagonists,”J. Med. Chem., vol. 33, pp. 1805-1811, (1990), American Chemical Society, UK.
Rovnyak, et al., “Active Conformation of 1,4-Dihydropyridine Calcium Entry Blockers. Effect of Size of 2-Aryl Substituent on Rotameric Equilibria and Receptor Binding,”J. Med. Chem., vol. 34, pp. 2521-2524, (1991), American Chemical Society.
Goldmann, et al., “Synthesis, Pharmacological Effects, and Conformation of 4,4-Disubstituted 1,4-Dihydropyridines,”J. Med. Chem., vol. 33, pp. 1413-1418, (1990), American Chemical Society.
Atwal, et al., “Dihydropyrimidine Calcium Channel Blockers: 2-Heterosubstituted 4-Aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines,”J. Med. Chem., vol. 33, pp. 1510-1515, (1990), American Chemical Society.
Atwal, et al., “Dihydropyrimidine Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines,”J. Med. Chem., vol. 33, pp. 2629-2635, (1990), American Chemical Society.
Alker, et al., “Long-Acting Dihydropyridine Calcium Antagonists. 4. Synthesis and Structure-Activity Relationships for a Series of Basic and Nonbasic Derivatives of 2-[(2-Aminoethoxy)methyl]-1,4-dihydropyridine Calcium Antagonists,”J. Med. Chem., vol. 33, pp. 585-591, (1990), American Chemical Society.
Natale, et al., “Lipophilic 4-Isoxazolyl-1,4-dihydropyridines: Synthesis and Structure-Activity Relationships,”J. Med. Chem., vol. 42, pp. 3087-3093, (1999), American Chemical Society.
Malhotra et al., “Barnidipine,” Drugs, vol. 61, pp. 989-996, (2001), Auckland, New Zealand.
Joslyn, et al., “Dimeric 1,4-Dihydropyridines as Calcium Channel Antagonists,”J. Med. Chem., vol. 31, pp. 1489-1492, (1988), American Chemical Society.
Alker, et al., “Long-Acting Dihydropyridine Calcium Antagonists. 3. Synthesis and Structure-Activity Relationships for a Series of 2-[(Heterocyclylmethoxy)methyl] Derivatives.”J. Med. Chem., vol. 32, pp. 2381-2388, (1989), American Chemical Society.
Novinson, et al., “3-Substituted 5,7-Dimethylpyrazolo[1,5-α]pyrimidines, 3′,5′-Cyclic-AMP Phosphodiesterase Inhibitors,”J. Med. Chem., vol. 17, No. 6, pp. 645, 648, (1974).
Weishaar, et al., “A New Generation of Phosphodiesterase Inhibitors: Multiple Molecular Forms of Phosphodiesterase and the Potential for Drug Selectivity,”J. Med. Chem., vol. 28, No. 5, pp. 537-545, (1985), American Chemical Society, USA.
Coates, et al., “Cyclic Nucleotide Phosphodiesterase Inhibition by Imidazopyridines: Analogues of Sulmazole and Isomazole as Inhibitors of the cGMP Specific Phosphodiesterase,”J. Med. Chem., vol. 36, pp. 1387-1392, (1993), American Chemical Society.
Marivet, et al., “Inhibition of Cyclic Adenosine-3′,5′-monophosphatae Phosphodiesterase from Vascular Smooth Muscle by Rolipram Analogues,”J. Med. Chem., vol. 32, pp. 1450-1457, (1989) American Chemical Society.
Moos, et al., “Cardiotonic Agents. 8. Selective Inhibitors of Adenosine 3′,5′-Cyclic Phosphate Phosphodiesterase III. Elaboration of a Five-Point Model for Positive Inotropic Activity,”J. Med. Chem., vol. 30, pp. 1963-1972, (1987), American Chemical Society.
Venuti, et al., “Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazo[2,1-b]quinazoline,”J. Med. Chem., vol. 31, pp. 2136-2145, (1988), American Chemical Society.
Venuti, et al., “Inhibitors of Cyclic AMP Phosphodiesterase. 4. Synthesis and Evaluation of Potential Prodrugs of Lixazinone,”J. Med. Chem., vol. 31, pp. 2145-2152, (1988), American Chemical Society.
Sircar, et al., “Cardiotonic Agents, 7. Inhibition of Separated Forms of Cyclic Nucleotide Phosphodiesterase from Guinea Pig Cardiac Muscle by 4,5-Dihydro-6-[4-(1-H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and Related Compounds. Structure-Activity Relationships and Correlation with in Vivo Positive Inotropic Activity,”J. Med. Chem., vol. 30, pp. 1955-1962, (1987), American Chemical Society.
Sircar, et al., “Cardiotonic Agents. 9. Synthesis and Biological Evaluation of a Series of (E)-4,5-Dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3(2H)-pyridazinones: A Novel Class of Compounds with Positive Inotropic, Antithrombotic, and Vasodilatory Activities for the Treatment of Congestive Heart Failure,&
Hamilton Gregory S.
Leighton Harry Jefferson
Artesian Therapeutics, Inc.
Seed IP Law Group PLLC
LandOfFree
Compounds having simultaneous ability to block L-type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having simultaneous ability to block L-type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having simultaneous ability to block L-type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3696287